Panacea Biotec: No Shares Dematerialized in June 2026
Panacea Biotec Limited reported no shares were dematerialized in June 2026. As of June 30, 2026, the total dematerialized shares were 6,11,05,526 (NSDL: 5,24,78,317; CDSL: 86,27,209). This information was confirmed by the company's RTA, Skyline Financial Services Pvt. Ltd.
This is a routine disclosure of dematerialization data, which is a standard compliance requirement and typically has no direct impact on the company's stock price or business operations.
The announcement is a routine regulatory filing regarding share dematerialization status and does not contain any significant positive or negative financial or operational news.
Panacea Biotec Limited has submitted its dematerialization status report for the month of June 2026 to the stock exchanges. As per the report, no shares of the company were dematerialized during June 2026.
The total number of shares dematerialized as of June 30, 2026, stood at 6,11,05,526. This includes 5,24,78,317 shares held with NSDL and 86,27,209 shares held with CDSL.
The company has also provided a certificate from its Registrar and Share Transfer Agent (RTA), Skyline Financial Services Pvt. Ltd., confirming these dematerialization details as of June 30, 2026. The RTA's report also indicates no change in the total dematerialized shares from May 30, 2026, to June 30, 2026.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under shareholding pattern. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.